跳至主要内容
临床试验/NL-OMON56160
NL-OMON56160招募中不适用

TOwards Personalized multi-modality esophageal cancer treatment using machine learning-based Quantitative MRI - TOP-QMRI

Amsterdam UMC0 个研究点目标入组 65 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Patients with biopsy-proven esophageal cancer (adenocarcinoma)
  • 2. WHO-performance score 0-2.
  • 3. Written informed consent.
  • For sub-study III, subjects must also meet the following criterium:
  • 4. Planned for neoadjuvant chemoradiotherapy and surgery with curative intent
  • (cT1-4a, N0-3, M0)

排除标准

  • 1. Contra-indications for MR scanning.
  • 2. Contra-indications for Gadolinium-based contrast injection, including known
  • renal insufficiency (eGFR<30 ml/min/1.73m2) and known allergic reaction to
  • gadolinium-based contrast agent.
  • 3. Age < 18 years
  • For sub-study III, potential subjects who meet the following criteria will be
  • excluded from participation in this study:
  • 4. Previous treatment for esophageal cancer

研究者

发起方
Amsterdam UMC

相似试验